Keeping It Simple

[eastunder]

CAPR

4-29-20

9.09

Note: currently + 8.45/+250% on following news...

April 29, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment and prevention of diseases, announced today new data reporting 100 percent survival in critical COVID-19 patients who were treated with Capricor’s lead asset, off-the-shelf (“allogeneic”) cardiac cell therapy CAP-1002, at Cedars-Sinai Medical Center as part of six compassionate care cases.
https://finance.yahoo.com/news/capricor-data-reports-100-percent-131510422.html

Capricor Therapeutics (Nasd: CAPR)

SEC, nasdaq,

ShortSqueeze, yahoo

Finviz, StockTA, Stoxline,









Capricor Therapeutics (CAPR) has 2 splits in CAPR split history database.

November 12, 1997...1 for 10 reverse split,
June 05, 2019...1 for 10 reverse split